A Randomized Phase 2 Trial of Gemcitabine/Cisplatin With or Without Cetuximab in Patients With Advanced Urothelial Carcinoma

BACKGROUND: Epidermal growth factor receptor overexpression is associated with poor outcomes in urothelial carcinoma (UC). Cetuximab (CTX) exhibited an antitumor effect in in vivo UC models. The efficacy of gemcitabine/cisplatin (GC) with or without CTX in patients with advanced UC was evaluated. ME...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Hussain, Maha, Daignault, Stephanie, Agarwal, Neeraj, Grivas, Petros D., Siefker-Radtke, Arlene O., Puzanov, Igor, MacVicar, Gary R., Levine, Ellis Glenn, Srinivas, Sandy, Twardowski, Przemyslaw, Eisenberger, Mario A., Quinn, David I., Vaishampayan, Ulka N., Yu, Evan Y., Dawsey, Scott, Day, Kathleen C., Day, Mark L., Al-Hawary, Mahmoud, Smith, David C.
Format: Artigo
Idioma:Inglês
Publicat: 2014
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4142676/
https://ncbi.nlm.nih.gov/pubmed/24802654
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28767
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars